EA033197B1 - Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b - Google Patents

Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b

Info

Publication number
EA033197B1
EA033197B1 EA201890245A EA201890245A EA033197B1 EA 033197 B1 EA033197 B1 EA 033197B1 EA 201890245 A EA201890245 A EA 201890245A EA 201890245 A EA201890245 A EA 201890245A EA 033197 B1 EA033197 B1 EA 033197B1
Authority
EA
Eurasian Patent Office
Prior art keywords
azaindoles
substituted
receptor modulators
nr2b
glun2b receptor
Prior art date
Application number
EA201890245A
Other languages
English (en)
Other versions
EA201890245A1 (ru
Inventor
Криста К. Кровиан
Майкл А. Летавич
Джейсон К. Рех
Акинола Сойод-Джонсон
Джессика Л. Уолл
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201890245A1 publication Critical patent/EA201890245A1/ru
Publication of EA033197B1 publication Critical patent/EA033197B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

Замещенные 4-азаиндолы формулы (I) в качестве лигандов подтипа 2В (NR2B) N-метил-D-аспартатного рецептора. Соединения можно использовать для модуляции подтипа 2В (NR2B) N-метил-D-аспартатного рецептора, а также в фармацевтических композициях и способах лечения заболеваний, расстройств и состояний, опосредованных активностью подтипа 2В (NR2B) N-метил-D-аспартатного рецептора.
EA201890245A 2015-07-09 2016-07-07 Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b EA033197B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562190416P 2015-07-09 2015-07-09
PCT/US2016/041339 WO2017007938A1 (en) 2015-07-09 2016-07-07 Substituted 4-azaindoles and their use as glun2b receptor modulators

Publications (2)

Publication Number Publication Date
EA201890245A1 EA201890245A1 (ru) 2018-06-29
EA033197B1 true EA033197B1 (ru) 2019-09-30

Family

ID=56497884

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890245A EA033197B1 (ru) 2015-07-09 2016-07-07 Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b

Country Status (25)

Country Link
US (2) US9963447B2 (ru)
EP (1) EP3319963B1 (ru)
JP (2) JP6964576B2 (ru)
KR (1) KR20180026760A (ru)
CN (1) CN108026094B (ru)
AU (1) AU2016291158B2 (ru)
BR (1) BR112018000468A2 (ru)
CA (1) CA2991765C (ru)
CY (1) CY1123007T1 (ru)
DK (1) DK3319963T3 (ru)
EA (1) EA033197B1 (ru)
ES (1) ES2781867T3 (ru)
HK (1) HK1255160A1 (ru)
HR (1) HRP20200410T1 (ru)
HU (1) HUE047460T2 (ru)
IL (1) IL256758A (ru)
LT (1) LT3319963T (ru)
MA (1) MA42397B1 (ru)
MD (1) MD3319963T2 (ru)
MX (1) MX2018000352A (ru)
PL (1) PL3319963T3 (ru)
PT (1) PT3319963T (ru)
SI (1) SI3319963T1 (ru)
WO (1) WO2017007938A1 (ru)
ZA (1) ZA201800827B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3180315B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Pyrazoles
DK3180329T3 (da) 2014-08-15 2020-04-06 Janssen Pharmaceuticals Inc Triazoler som nr2b receptorinhibitorer
CN108026094B (zh) 2015-07-09 2021-02-09 詹森药业有限公司 取代的4-氮杂吲哚以及它们作为glun2b受体调节剂的用途
CN109071488B (zh) 2016-02-10 2021-08-13 詹森药业有限公司 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
WO2019193516A2 (en) 2018-04-04 2019-10-10 Janssen Pharmaceutica Nv Substituted pyridine and pyrimidines and their use as glun2b receptor modulators
AU2020290772A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
CA3143102A1 (en) * 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo[4,3-b]pyridines and their use as glun2b receptor modulators
JP2022538774A (ja) 2019-06-14 2022-09-06 ヤンセン ファーマシューティカ エヌ．ベー． ピリジンカルバメート及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用
CA3142996A1 (en) * 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
WO2020249802A1 (en) * 2019-06-14 2020-12-17 Janssen Pharmaceutica Nv Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
MX2021015503A (es) * 2019-06-14 2022-04-20 Janssen Pharmaceutica Nv Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b.
CN114621125B (zh) * 2020-12-14 2024-07-09 中国科学技术大学 Nlrp3炎症小体抑制剂及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082868A1 (en) * 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
US20070275965A1 (en) * 2006-03-30 2007-11-29 Chemocentryx, Inc. CXCR4 modulators
US20080300239A1 (en) * 2007-05-18 2008-12-04 Adams Nicholas D Quinoline derivatives as pi3 kinase inhibitors
WO2010043396A1 (en) * 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2014124651A1 (en) * 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080379A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
CA2686651C (en) 2007-05-25 2015-11-24 Abbott Gmbh & Co. Kg Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor)
US20100325949A1 (en) 2007-07-03 2010-12-30 Edward Scott Carlson Support apparatus for climbing plants
TW200913993A (en) 2007-08-30 2009-04-01 Takeda Pharmaceutical Substituted pyrazole derivatives
WO2009058261A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation of sleep with nr2b receptor antagonists
CA2719749A1 (en) 2008-03-27 2009-10-01 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
JP5630867B2 (ja) 2008-08-05 2014-11-26 第一三共株式会社 イミダゾピリジン−２−オン誘導体
US8877772B2 (en) 2008-11-25 2014-11-04 University Of Rochester Substituted pyrrolo[2,3-B]pyridines as MLK inhibitors
TWI598347B (zh) * 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2011156245A2 (en) 2010-06-09 2011-12-15 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
AU2014244183A1 (en) * 2013-03-13 2015-08-13 Abbvie Inc. Pyridine CDK9 kinase inhibitors
MX2015012456A (es) * 2013-03-15 2016-02-03 Plexxikon Inc Compuestos heterociclicos y usos de los mismos.
CN103626767A (zh) * 2013-12-04 2014-03-12 上海药明康德新药开发有限公司 区域选择性的氮杂吲哚及其合成方法
EP3180315B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Pyrazoles
DK3180329T3 (da) 2014-08-15 2020-04-06 Janssen Pharmaceuticals Inc Triazoler som nr2b receptorinhibitorer
CN108026094B (zh) 2015-07-09 2021-02-09 詹森药业有限公司 取代的4-氮杂吲哚以及它们作为glun2b受体调节剂的用途
CN109071488B (zh) 2016-02-10 2021-08-13 詹森药业有限公司 取代的1,2,3-三唑作为nr2b-选择性nmda调节剂
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082868A1 (en) * 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
US20070275965A1 (en) * 2006-03-30 2007-11-29 Chemocentryx, Inc. CXCR4 modulators
US20080300239A1 (en) * 2007-05-18 2008-12-04 Adams Nicholas D Quinoline derivatives as pi3 kinase inhibitors
WO2010043396A1 (en) * 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2014124651A1 (en) * 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUONARATI M H, TURTELTAUB K W, SHEN N H, FELTON J S: "Role of sulfation and acetylation in the activation of 2-hydroxyamino-1-methyl-6-phenyl-imidazo[4,5-b]pyridine to intermeidates which bind DNA", MUTATION RESEARCH LETTERS, ELSEVIER, NL, vol. 245, no. 3, 1 November 1990 (1990-11-01), NL, pages 185 - 190, XP002760909, ISSN: 0165-7992, DOI: 10.1016/0165-7992(90)90048-O *

Also Published As

Publication number Publication date
CN108026094B (zh) 2021-02-09
KR20180026760A (ko) 2018-03-13
ES2781867T3 (es) 2020-09-08
CA2991765A1 (en) 2017-01-12
EA201890245A1 (ru) 2018-06-29
MD3319963T2 (ro) 2020-05-31
MX2018000352A (es) 2018-08-15
DK3319963T3 (da) 2020-02-03
WO2017007938A1 (en) 2017-01-12
PT3319963T (pt) 2020-04-09
JP2018520170A (ja) 2018-07-26
MA42397B1 (fr) 2020-02-28
PL3319963T3 (pl) 2020-06-01
US20170008890A1 (en) 2017-01-12
LT3319963T (lt) 2020-03-25
CN108026094A (zh) 2018-05-11
JP6964576B2 (ja) 2021-11-10
AU2016291158A1 (en) 2018-02-01
IL256758A (en) 2018-03-29
AU2016291158B2 (en) 2020-04-30
US9963447B2 (en) 2018-05-08
HRP20200410T1 (hr) 2020-08-21
HUE047460T2 (hu) 2020-04-28
JP7369743B2 (ja) 2023-10-26
US20180208595A1 (en) 2018-07-26
EP3319963A1 (en) 2018-05-16
CA2991765C (en) 2023-10-03
BR112018000468A2 (pt) 2018-09-18
SI3319963T1 (sl) 2020-02-28
JP2021193099A (ja) 2021-12-23
HK1255160A1 (zh) 2019-08-09
US10377753B2 (en) 2019-08-13
CY1123007T1 (el) 2021-10-29
EP3319963B1 (en) 2020-01-08
ZA201800827B (en) 2019-09-25

Similar Documents

Publication Publication Date Title
EA033197B1 (ru) Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
SA518391624B1 (ar) Ror- منظمات جاما
NZ737399A (en) Ccr2 modulators
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
SA521422031B1 (ar) مركبات 2 – فورميل – 3 – هيدروكسي فينيلوكسي ميثيل قادرة على تعديل الهيموجلوبين
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
UA122868C2 (uk) Тетрагідропіридо[3,4-в]індолові модулятори естрогенових рецепторів та їх застосування
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
JOP20210330A1 (ar) مركبات بيرازولو-بيريدين عطرية غير متجانسة مستبدلة واستخدامها كمعدِّلات لمستقبل الغلوتومات "glun2b"
GB2533454A (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2021015506A (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b.
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
MX2016008898A (es) Antagonistas selectivos de nr2b.
GEP20186893B (en) Pyrazines modulators of gpr6
MX2019011265A (es) Derivados del acido acetico azaindol y su uso como moduladores de receptor de prostaglandina d2.
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016011900A (es) Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU